Clinical Trial Update: Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Mayo Clinic-sponsored phase 1/2 trial evaluating a personalized neoantigen peptide-based vaccine in combination with pembrolizumab for advanced solid tumors, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Endometrial Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• personalized neoantigen peptide-based vaccine

Snippet

Sponsor: Mayo Clinic | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1, Phase 2 | Status: RECRUITING